Investors keen on high-yield dividend stocks faced a tough market landscape in recent times. Even though the stock market boomed, yields for S&P 500 stocks plummeted to around 1.3%. Yet, amid this turbulence, some companies managed to hold or even hike their dividends, presenting potential openings for those seeking income.
Western Union: Dividend Dilemma Amid Declining Numbers
Western Union's stock saw a staggering drop of over 50% since its peak in 2020. In the second quarter of that year, it processed about 293.2 million consumer money transfer transactions—a modest 4% bump from the prior year but only slightly above figures seen back in 2019.
The attraction lies in Western Union's hefty dividend yield of around 7.9%. However, those eyeing growth will likely be disappointed; the dividend has stagnated at $0.235 per share since early 2021. To add insult to injury, its revenue took a hit—down by 7% year-over-year—as geopolitical factors affected dollar transactions in Iraq and total revenue fell by 9%. The scrutiny surrounding its growth prospects has intensified.
This company’s long-standing reputation as an international remittance titan enables it to charge premium fees over newer entrants like Wise, which reported an impressive transfer volume increase of about 18%. Smaller competitors like Remitly have also made waves; their revenues surged by 31% last quarter. With Western Union projecting total revenues between $4.125 billion and $4.2 billion for the year—a decline of approximately 6.5% from last year—the viability of its business model deserves a serious look.
“Valuation sits at just 7.4 times trailing earnings, but earnings are declining.”
This isn’t just about dividends; it’s about survival as competition heats up across the sector.
Royalty Pharma: A Unique Growth Narrative
On another note, Royalty Pharma operates differently within the biopharmaceutical realm—it plays the role of a lender targeting capital-hungry ventures while promising steady returns through royalties on successful drug sales. Currently offering a yield near 3%, it seems poised for future increases as they grow.
The company aids start-up drug developers who often struggle with consistent revenue streams during their formative years—an approach that fills a notable gap in this volatile industry. Over ten years, Royalty Pharma’s portfolio receipts have soared at an annual rate of around 13%, signaling adept borrower selection and robust financial health.
